British pharmaceutical giant AstraZeneca's breast cancer drug Faslodex (fulvestrant, fulvestrant) has recently received great news in EU regulation. The European Commission (EC) has approved Faslodex for first-line treatment of postmenopausal women with estrogen receptor-positive (ER+) locally advanced or metastatic breast cancer who have not previously received endocrine therapy. The approval is based on positive data from FALCON, a phase III clinical trial of breast cancer. The study was a randomized, double-blind, multicenter study of Faslodex 500 mg injection in postmenopausal women with hormone receptor-positive (HR+) locally advanced or metastatic breast cancer who had not received any hormonal therapy. Compared with AstraZeneca's breast cancer drug aromatase inhibitor Arimidex 1mg tablets (brand name: Ruining, common name: anastrozole, anastrozole) for the efficacy and safety of first-line treatment. The study data confirmed that Faslodex was significantly superior to Arimidex in first-line treatment: the median progression-free survival (PFS) was significantly prolonged in the Faslodex 500 mg treatment group compared with the Arimidex 1 mg treatment group (16.6 months vs 13.8 months). , HR=0.797, 95% CI: 0.637-0.999, p=0.0486), reached the primary endpoint of the study. Currently, in the first-line treatment of postmenopausal women with HR+ advanced breast cancer, aromatase inhibitors (such as Arimidex) are standard care drugs. Faslodex 500 mg significantly prolongs progression-free survival compared to Arimidex 1 mg, indicating that the drug will provide an earlier treatment option for postmenopausal women with locally advanced or metastatic HR+ breast cancer. In this study, the safety and tolerability of Faslodex and Arimidex were consistent with the currently known treatment experience for each drug. The most common adverse events (AE) for Faslodex and Arimidex included arm and joint pain (16.7% vs. 10.3%), hot flashes (11.4% vs. 10.3%), and nausea (10.5% vs. 10.3%). Jamie Freedman, head of AstraZeneca's oncology business unit and executive vice president, said the EU's first-line treatment approval demonstrates the scientific strength of Faslodex's more than 15 years of clinical experience. Now, postmenopausal women with HR+ advanced breast cancer can benefit from Faslodex treatment in the early stages of the disease. The company will continue to explore the full potential of this important drug, such as monotherapy and combination with other drugs. The study's lead researcher, Dr. Matthew Ellis, director of the Bayer School of Medicine's Liszt and Hugh-Smith Breast Center, said data from the FALCON study showed that Faslodex was used in first-line treatment to significantly increase disease risk or death risk compared with standard care. A 20% reduction is a major advancement in the clinical treatment of postmenopausal women with HR+ advanced breast cancer who have not received treatment. Research evidence suggests that early application of Faslodex in these patients will significantly delay the progression of the disease. Faslodex is the only hormonal drug used in the treatment of advanced breast cancer, which delays tumor growth by binding to and degrading estrogen receptors. In some patients, estrogen receptors are a key driver of breast cancer progression. Currently, Faslodex has been widely approved for the treatment of post-menopausal women with HR+advanced breast cancer after anti-estrogen therapy. Faslodex was first approved for marketing in 2002, and AstraZeneca is currently testing more than 19 Faslodex combination regimens for the therapeutic potential of HR+ advanced breast cancer patients. Breast cancer is the number one common malignancy in the female population, and advanced breast cancer (ABC) refers to stage III and IV breast cancer. Stage III is also known as local advanced stage, and stage IV refers to metastatic breast cancer. This is also the most advanced stage, and cancer cells have spread from the breast to other parts of the body. At present, there is no medicine to cure advanced breast cancer. In clinical practice, the treatment goal of advanced breast cancer is to delay the deterioration or death of the disease.
B/W Ultrasound Scanner,B/W Full Digital Ultrasound Scanner,Portable B/W Ultrasound Scanner,Wireless Ultrasound Scanner
Professional B/W Ultrasound Scanner manufacturer is located in China, including B/W Full Digital Ultrasound Scanner,Portable B/W Ultrasound Scanner,Wireless Ultrasound Scanner, etc.
Clinical value B/W Ultrasound Scanner,B/W Full Digital Ultrasound Scanner,Portable B/W Ultrasound Scanner,Wireless Ultrasound Scanner Guangzhou Sonostar Technologies Co., Limited , https://www.sonoeye.com
Precision medicalvisualization tool, first aid quick examination, basic examination, wireless ultrasound probe is not only help the medical workers to improve working efficiency, reduce labor intensity and working pressure, but also improve diagnostic confidence and treatment.Minimize diagnostic and treatment errors, complications, sequelae, medical accidents and disputes
Application directions
1. Visualization tools: invasive intervention guide, surgical and therapy guidance.
2. Emergency inspection: ER, ICU, Wild First Aid, battlefieldrescue.
3. Preliminary examination: Ward Inspection, primary clinicexamination medical examination, health screening,home care, family planning, etc.
4. Remote diagnosis, consultation, training: works on smart phone or tablet, easy telecommunications.
Applicable Clinic
Anaesthesia, pain, ICU, urology, nephrology, cardiology, rehabilitation, orthopedics, gynaecology, reproductive, obstetrics, neonatology, pneumology, gastroenterology, hepatological surgery, general surgery, vascular surgery, thyroid surgery, skull surgery, neurology, transplantation, ophthalmology, dermatology, emergency, nursing, inpatient, physical examination, and ER ambulance, primary care, family planning centers, family medicine, home care, nursing home, prisons, plastic surgery, small needle knife/acupuncture treatment clinic, sports medicine, battle field ambulance, disaster ambulance, etc.
Example of usages
Puncture/intervention guide: thyroid ablation, neck vein puncture, subclavian vein puncture, and neck and arm nerves, canal of arantius, spine puncture, radial vein injection, percutaneous renal surgery guide, hemodialysis catheter/thrombosis monitoring, abortion, bile duct puncture, hydropsarticuli extraction, pain therapy and cosmetic surgery, urine catheterization. Emergency inspection:internal bleeding, Pleural effusion, pneumothorax, Atelectasis of lung, Temporal / posterior auricular fistula, pericardial effusion. Daily inspection:thyroid, breast, liver cirrhosis, fatty liver, prostate/pelvics, stroke screening, retinal artery, uterus, follicular monitoring, fetus, musculoskeletal, podiatry, fractures, varicose veins, spleen, bladder/urinary function, urine volume measurement.